Atara Biotherapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $145.49 million
- Book Value:
- Revenue TTM:
- $57.49 million
- Operating Margin TTM:
- Gross Profit TTM:
- $63.57 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Atara Biotherapeutics Inc had its IPO on 2014-10-16 under the ticker symbol ATRA.
The company operates in the Healthcare sector and Biotechnology industry. Atara Biotherapeutics Inc has a staff strength of 330 employees.
Shares of Atara Biotherapeutics Inc opened at $1.5 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.46 - $1.57, and closed at $1.54.
This is a +2.67% increase from the previous day's closing price.
A total volume of 2,211,943 shares were traded at the close of the day’s session.
In the last one week, shares of Atara Biotherapeutics Inc have slipped by -19.79%.
Atara Biotherapeutics Inc's Key Ratios
Atara Biotherapeutics Inc has a market cap of $145.49 million, indicating a price to book ratio of 1.9674 and a price to sales ratio of 4.5385.
In the last 12-months Atara Biotherapeutics Inc’s revenue was $57.49 million with a gross profit of $63.57 million and an EBITDA of $-256026000. The EBITDA ratio measures Atara Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Atara Biotherapeutics Inc’s operating margin was -454.56% while its return on assets stood at -46.7% with a return of equity of -148.63%.
In Q1, Atara Biotherapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 83.2%.
Atara Biotherapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Atara Biotherapeutics Inc’s profitability.
Atara Biotherapeutics Inc stock is trading at a EV to sales ratio of 2.3103 and a EV to EBITDA ratio of -0.5619. Its price to sales ratio in the trailing 12-months stood at 4.5385.
Atara Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $302.08 million
- Total Liabilities
- $67.88 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Atara Biotherapeutics Inc ended 2023 with $302.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $302.08 million while shareholder equity stood at $64.96 million.
Atara Biotherapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $67.88 million in other current liabilities, 10000.00 in common stock, $-1767795000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.74 million and cash and short-term investments were $205.41 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Atara Biotherapeutics Inc’s total current assets stands at $224.18 million while long-term investments were $0 and short-term investments were $156.67 million. Its net receivables were $397000.00 compared to accounts payable of $5.07 million and inventory worth $5.34 million.
In 2023, Atara Biotherapeutics Inc's operating cash flow was $-6007000.00 while its capital expenditure stood at $399000.
Comparatively, Atara Biotherapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Atara Biotherapeutics Inc stock is currently trading at $1.54 per share. It touched a 52-week high of $9.34 and a 52-week low of $9.34. Analysts tracking the stock have a 12-month average target price of $16.13.
Its 50-day moving average was $2.52 and 200-day moving average was $3.71 The short ratio stood at 9.03 indicating a short percent outstanding of 0%.
Around 162.6% of the company’s stock are held by insiders while 10398.2% are held by institutions.
Frequently Asked Questions About Atara Biotherapeutics Inc
Similar Industry Stocks (Biotechnology)
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.